Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis

Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by multisystemic manifestations including asthma. Mepolizumab (300 mg/4 weeks) has recently been approved for EGPA. However, real-life data are scarce and report experiences with high doses of mepolizumab intravenousl...

Descripción completa

Detalles Bibliográficos
Autores principales: Vultaggio, Alessandra, Nencini, Francesca, Bormioli, Susanna, Vivarelli, Emanuele, Dies, Laura, Rossi, Oliviero, Parronchi, Paola, Maggi, Enrico, Matucci, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346991/
https://www.ncbi.nlm.nih.gov/pubmed/32638567
http://dx.doi.org/10.4168/aair.2020.12.5.885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346991/
https://www.ncbi.nlm.nih.gov/pubmed/32638567
http://dx.doi.org/10.4168/aair.2020.12.5.885

Ejemplares similares